Novartis AG (XTER:NOT) Other Current Receivables: €187 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:NOT Novartis AG XTER:NOT
78 GF Score
Price €134.60
GF Value €113.29
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Other Current Receivables?

Novartis AG XTER:NOT 78 Other Current Receivables is €187 Mil as of Mar. 2026. GuruFocus rates XTER:NOT with a GF Score™ of 78/100 and a GF Value™ of €113.29 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Novartis AG's Other Current Receivables for the quarter that ended in Mar. 2026 was €187 Mil.

Novartis AG's quarterly Other Current Receivables increased from Sep. 2025 (€119.28 Mil) to Dec. 2025 (€1,705.44 Mil) but then stayed the same from Dec. 2025 (€1,705.44 Mil) to Mar. 2026 (€186.84 Mil).

Novartis AG's annual Other Current Receivables declined from Dec. 2023 (€2,080.67 Mil) to Dec. 2024 (€1,745.74 Mil) and declined from Dec. 2024 (€1,745.74 Mil) to Dec. 2025 (€1,705.44 Mil).

Novartis AG Other Current Receivables Related Terms

Novartis AG Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Novartis AG's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Other Current Receivables Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,430.16 1,725.63 2,080.67 1,745.74 1,705.44

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.33 104.04 119.28 1,705.44 186.84
XTER:NOT
78GF Score
Novartis AG XTER:NOT
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €187 Mil mean?
Novartis AG (XTER:NOT) has a Other Current Receivables of €187 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Novartis AG and its competitors.
Is Novartis AG's Other Current Receivables too high?
Novartis AG's current Other Current Receivables is €187 Mil. Overall, Novartis AG has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Other Current Receivables compare to LLY and JNJ?
Novartis AG's Other Current Receivables of €187 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Novartis AG and its competitors. Novartis AG's current Other Current Receivables is €187 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (XTER:NOT) is currently considered Modestly Overvalued. The stock's GF Value™ is €113.29, compared to a current price of €134.60 — trading 18.8% above its estimated fair value. The current Other Current Receivables is €187 Mil. Novartis AG's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Novartis AG (XTER:NOT), the current Other Current Receivables is €187 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (XTER:NOT) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €134.60 is trading 18.8% above its estimated GF Value™ of €113.29. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for XTER:NOT:

  • Other Current Receivables: €187 Mil
  • GF Value™: €113.29 vs. price of €134.60 (18.8% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the XTER:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
78GF Score

Get the complete analysis for XTER:NOT

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.60
Price
€113.29
GF Value